Abstract: This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.

Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Abstract: The present invention relates to an antibody construct comprising at least one antigen binding site specific for ICAM1 and at least one antigen binding site specific for at least one allergen.

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract: Provided herein are compositions and methods related to reducing the risk of or preventing fetal wastage in a subject using a CXCR3 inhibitor.

Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

Abstract: The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.

Abstract: Provided herein are antigen binding polypeptides and complexes thereof having agonist activity. Also provided are methods for screening for complexes or polypeptides having agonist activity, enhancing the agonist activity of a polypeptide, and for agonizing a cell surface receptor using the complexes and polypeptide described herein.

Abstract: The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.

Abstract: Provided herein are bi-specific chimeric antigen receptors (CARs), such as those specific for CD138 and BCMA. Use of the CARs in immune cells (e.g., T cells), compositions, and methods are also contemplated.

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.

Abstract: The present invention provides a catalyst precursor and a catalyst suitable for preparing multi-wall carbon nanotubes. The resulting multi-wall carbon nanotubes have a narrow distribution as to the number of walls forming the tubes and a narrow distribution in the range of diameters for the tubes. Additionally, the present invention provides methods for producing multi-wall carbon nanotubes having narrow distributions in the number of walls and diameters. Further, the present invention provides a composition of spent catalyst carrying multi-wall nanotubes having narrow distribution ranges of walls and diameters.

Abstract: The present disclosure relates to combination treatments with anti-androgen therapeutics, including enzalutamide, and prostate-specific membrane antigen (PSMA)-binding polypeptides including multi-specific polypeptide therapeutics that specifically target cells expressing PSMA and are capable of redirecting T-cell cytotoxicity. Such therapeutics are useful for the treatment of prostate cancer (e.g., castration-resistant prostate cancer). In one embodiment, multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides compositions comprising the multi-specific polypeptide therapeutics and one or more anti-androgen therapeutics.

Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.

Abstract: The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.

Abstract: Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, and chimeric antigen receptors (CARs) directed against the human FAP antigen as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.

Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.

Abstract: The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.

Abstract: The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.

Abstract: A chimeric antigen receptor specific for the extracellular membrane-proximal domain (EMPD) of membrane-bound IgE (mIgE) is provided. The EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon EMPD binding. Nucleic acids and vectors encoding the EMPD-specific chimeric antigen receptor are provided. T cells transduced with such vectors find use in chimeric antigen receptor-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.

Abstract: Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Abstract: The present invention relates to multi-functional proteins which comprise (i) a signal peptide, (ii) a target specific recognition domain, (iii) a linker region, connecting domain (ii) and domain (iv) which comprises a specific modified hinge region of the human CD8 alpha-chain, and (iv) an effector domain. The present invention furthermore relates to nucleic acids encoding the proteins, expression constructs for expressing the protein in a host cell and host cells. The proteins of the invention are chimeric antigen receptors with an optimized linker or hinge region that are suitable for generating target-specific effector cells, for use as a medicament, in particular in the treatment of cancer and in adoptive, target-cell specific immunotherapy.

Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.

Abstract: An object of the present invention is to provide a polydimethylsiloxane substrate to which a peptide having an affinity for polydimethylsiloxane (PDMS) is bound; a method for immobilizing a target protein on a polydimethylsiloxane substrate; a peptide having an affinity for PDMS; a polynucleotide encoding a peptide having an affinity for PDMS; and a vector using thereof. A polydimethylsiloxane substrate to which a peptide having an affinity for polydimethylsiloxane is bound, the peptide comprising the following peptide (1a) or (1b), or a fragment thereof: (1a) a peptide comprising an amino acid sequence represented by at least one member selected from the group consisting of SEQ ID NOs: 1 to 9; and (1b) a peptide comprising the amino acid sequence of (1a) in which one or more amino acids are deleted, substituted, and/or added, the peptide having an affinity for polydimethylsiloxane.

Abstract: Various embodiments disclosed relate to a nanoparticle-protein complex for intracellular protein delivery. In various embodiments, the present invention provides a nanoparticle-protein complex including a nanoparticle including an amine-containing ligand. The nanoparticle-protein complex also includes a protein comprising a carboxylic acid-containing tag.

Abstract: An object is to provide a method for producing a polysaccharide derivative without using a catalyst, a cocatalyst, or an active compound by esterification, etherification, or the like, from a polysaccharide such as cellulose as a source material, while maintaining a high molecular weight. Another object is to provide a method for producing a cellulose derivative in a separated condition directly from biomass containing lignocellulose. A method for producing a polysaccharide derivative of the present invention is characterized in that a reaction is carried out in a mixture comprising: a source material comprising a polysaccharide; an ionic liquid for which the pKa of a conjugate acid of an anion in DMSO is 12 to 19 and which is capable of producing a carbene; and a chain or cyclic ester compound or an epoxy compound. Preferably as a source material containing a polysaccharide, a biomass source material containing lignocellulose is used.

Abstract: The resent invention relates to biodegradable microspheres having a diameter of 1-2000 ?m comprising cross-linked hydrolysed starch onto which at least one type of ligand has been coupled via a carboxylic ester bond. The ligand shall be an endogenous, charged molecule with a molecular mass of less than 1000 Da comprising at least one additional carboxylic acid function in addition to the one utilised for coupling the ligand to the micro-sphere and/or at least one amine function. On average 0.05-1.5 ligands are coupled to each glucose moiety in the hydrolysed starch.

Abstract: Compositions comprising oxidized dextran compounds are disclosed herein. Oxidized dextran compounds are produced by contacting dextran under aqueous conditions with at least one N-oxoammonium salt, at least one periodate compound, and/or at least one peroxide compound.

Abstract: There are provided a modified liquid diene rubber that can be used for a curable resin composition and a resin composition containing the modified liquid diene rubber. The curable resin composition containing the modified liquid diene rubber has a much higher curing rate than that in the related art, and the resulting cured product has excellent mechanical properties, transparency, and heat resistance. Produced are a modified liquid diene rubber and a resin composition containing the modified liquid diene rubber. The modified liquid diene rubber includes a modifying group (p) partly containing a (meth)acryloyl group therein and a monomer unit (a1) derived from a conjugated diene compound. A carbon-carbon double bond derived from the conjugated diene compound has a hydrogenation rate of 30 to 95 mol %, and the modifying group (p) has a functional group equivalent weight of 700 to 20,000 g/eq.

Abstract: A water dispersion of gel particles, a method of producing the water dispersion, and an image forming method using the water dispersion. The gel particles have a three-dimensional crosslinked structure including a structural unit represented by Formula (1) and a urea bond, have a hydrophilic group and a polymerizable group, include photopolymerization initiators and are dispersed in water. In Formula (1), R1 represents H or an alkyl group; X1 represents hydrogen, halogen, a hydroxyl group, an alkyl group, a cyano group, a lactam group, a —C(?O)X2R2 group, an —OC(?O)R3 group, or an aryl group; X2 represents oxygen or an —N(RX2)— group; RX2 and R2 represent a hydrocarbon group that may contain a hetero atom or H; R2 and RX2 may be bonded to each other to form a ring, and R3 represents a hydrocarbon group that may contain a hetero atom.

Abstract: Disclosed herein is a polymerization process involving the steps of generating monomer micro-volumes in a microfluidic device, feeding the monomer micro-volumes through the at least one first microfluidic channel towards a monomer feed point at which the monomer micro-volumes enter into or onto a volume of a non-aqueous liquid and form aqueous monomer droplets, allowing the aqueous monomer droplets to flow towards a polymer bead discharge point, initiating polymerisation of the aqueous monomer droplets to form polymerising beads, removing a suspension of the polymer beads in the non-aqueous liquid from the vessel at the polymer bead discharge point, and recovering water soluble or water swellable polymer beads from the suspension. The present disclosure also includes an apparatus for performing the polymerization process and water soluble or water swellable polymer beads obtained by the polymerization process.

Abstract: An object of the present invention is to provide a photocurable composition from which a cured product having high concealing property is obtained by irradiation with an active energy ray such as ultraviolet ray, and which inhibits color fading of the cured product in a high temperature and high humidity (85 C and 85% RH) environment or a high temperature (100 C) environment. A photocurable composition including the following components (A) to (D): component (A): a leuco dye; component (B): a salt having an anion selected from the group consisting of [P(Rf)aF6-a]?, [Sb(Rf)bF6-b]? and [B(Rf)cF4-c]? (in the formulae, Rf represents a fluoroalkyl group having 1 to 20 carbon atoms, a and b each independently represent an integer of from 1 to 5, and c represents an integer of from 1 to 3); component (C): a radical polymerizable compound; and component (D): a photoradical initiator.

Abstract: A catalyst system is provided which comprises a solid support material having, on its surface, one or more catalytic transition metal complex wherein the solid support material comprises SiO2@AMO-LDH microspheres having the formula I: (i) wherein, Mz+ and M?y+ are two different charged metal cations; z=1 or 2; y=3 or 4; 0<x<0.9; b is 0 to 10; c is 0.01 to 10, preferably >0.01 and <10; p>0 q>0; Xn? is an anion with n>0, preferably 1?5a=z(1?x)+xy?2; and the AMO-solvent is an 100% aqueous miscible organic solvent. Preferably, M? in the formula I is Al. Preferably, M in the formula I is Li, Mg or Ca. The catalyst system has use in the polymerisation and/or copolymerisation of at least one olefm to produce a homopolymer and/or copolymer.

Abstract: Cross-linked tetrapolymers made up of different diallyl zwitterionic diallyl quaternary ammonium salt monomers, with one of them functioning as a cross-linking monomer. The cross-linked terpolymers include a repeating unit with multiple ligand centers that different metal ions can bind to. The cross-linked tetrapolymers are cationic, zwitterionic and anionic, and can be in either an acidic form or a basic form. A method of removing metal ions from an aqueous solution with these cross-linked tetrapolymers is also described.

Abstract: A dip-forming synthetic isoprene polymer latex contains a synthetic isoprene polymer which has been subjected to solution polymerization using an alkyllithium polymerization catalyst. A ratio between a mode diameter and a median diameter (mode diameter/median diameter) of a particle diameter of the latex is 0.8 or more. A Brookfield viscosity difference (V66?V56) between a Brookfield viscosity at a solid content concentration of 56% (V56) and a Brookfield viscosity at a solid content concentration of 66% (V66) is 200 mPa·s or less.

Abstract: A slurry polymerization process for the preparation of polyethylene in a reactor cascade of two or more polymerization reactors including the steps of feeding to a polymerization reactor amounts of ethylene, of a Ziegler catalyst, of fresh aluminum alkyl and of a diluent; feeding the slurry product withdrawn from the polymerization reactor to a second polymerization reactor; and feeding additional amounts of ethylene and of diluent wherein the ethylene is first passed through an ethylene purification unit, which reduces at least the concentration of carbon monoxide, carbon dioxide, oxygen, acetylene and water contained in the ethylene, before it is fed to the two or more polymerization reactors of the reactor cascade.

Abstract: This invention relates to high porosity (?15%) and/or low pore diameter (PD<165 ?m) propylene polymers and propylene polymerization processes using single site catalyst systems with supports having high surface area (SA?400 m2/g), low pore volume (PV?2 mL/g), a specific mean pore diameter range (PD=1-20 nm), and high average particle size (PS?30 ?m).

Abstract: Ethylene/1-butene copolymers made with a single site catalyst system have high melt strength and good processability.

Abstract: The invention provides compositions, each comprising an ethylene/alpha-olefin interpolymer, which has a reduced level of a low density, low molecular weight oligomeric fraction, as indicated by an HCC value, as described herein, and reduced levels of inorganic content or lower Tm. The invention also provides processes for forming such interpolymers.

Abstract: The invention provides a hydrophilizing agent which is to be added to a polymer having a large contact angle to produce a porous polymer film that has a small contact angle and that can maintain this small contact angle even after 168-hour contact with an aqueous sodium hypochlorite solution. The hydrophilizing agent contains a fluoropolymer having a contact angle of 50° or smaller and a weight reduction rate of 7% or lower.

Abstract: A copolymer is based on ?-?-unsaturated monocarboxylic acid, wherein the copolymer has a molar mass <100 000 g/mol. A process of preparing the copolymer compound includes mixing a copolymer in a melt with an impact modifier under action of shearing forces, a proportion of copolymer and impact modifier being selected preferably such that the copolymer forms a continuous phase and the impact modifier forms a discontinuous phase.

Abstract: The present invention relates to curable polyurethane polymers made from renewable materials. In particular isosorbide derived from glucose is used. These renewable materials may be formed into curable polyurethane polymer compositions having different chemical functionalities and cure mechanisms.

Abstract: When achieving high hardness by forming a hardcoat layer including only organic matter, cure shrinkage increases, a film on which the hardcoat layer is formed curls, and in extreme cases, the hardcoat layer is prone to cracking; on the other hand, when attempting to suppress cure shrinkage, it is difficult for sufficient high hardness to be exhibited. Furthermore, organic/inorganic hybrid curable resin compositions use inorganic matter such as silica in order to increase hardness. However, this leads to the problem of the inherent properties of the resin, such as workability, being lost. The abovementioned problems have been solved by a curable resin composition containing: a urethane (meth)acrylate, which is a reactant comprising norbornene diisocyanate and a compound having one hydroxyl group and one or more (meth)acryloyl groups in a molecule; and a (meth)acrylate monomer, which is a reactant comprising a polyol having a condensed polycyclic structure, and (meth)acrylic acid.

Abstract: To provide a fluorinated compound-containing composition which is capable of imparting excellent antifouling properties to an object (such as a hard coat layer) and which is excellent in compatibility and has foaming suppressed. This composition comprises the following fluorinated compound (A), the following compound (B) and a solvent (S1), wherein the content of the following fluorinated compound (A) in the composition is from 5 to 30 mass % to the composition, and the content of the following compound (B) is from 0.

Abstract: To provide a fluorinated compound capable of imparting excellent antifouling properties (oily ink repellency and fingerprint-stain removability) and abrasion resistance of the antifouling properties to an object (such as a hard coat layer). It is a reaction product of a compound (a1) having a poly(oxyperfluoroalkylene) chain and one active hydrogen-containing group, a compound (a2) having a poly(oxyperfluoroalkylene) chain and two active hydrogen-containing groups, a compound (b) having a polymerizable carbon-carbon double bond and an active hydrogen-containing group, and a polyisocyanate (c), wherein the proportion of the portion derived from the compound (a1) to the total (100 mass %) of the portion derived from the compound (a1) and the portion derived from the compound (a2) is from 60 to 99.9 mass %.

Abstract: The present invention relates to an organic zinc compound comprising a styrene-based polymer or a polyolefin-polystyrene block copolymer at both ends. Also, the present invention relates to a method for preparing the organic zinc compound, the method preparing an intermediate by coordination-polymerizing an olefin monomer using a transition metal catalyst, and then performing anionic polymerization by inserting an alkyllithium compound, an amine ligand, and a styrene-based monomer into the intermediate. Accordingly, the present invention can provide a method for preparing a commercially useful styrene-based polymer or polyolefin-polystyrene block copolymer directly from an olefin monomer and a styrene monomer in a one-pot manner.

Abstract: A method for producing a propulsion nozzle, wherein the nozzle is produced from an ablative resin, the method including a step of pre-polymerization wherein an innovative aldehyde compound is used.

Abstract: An aqueous polyurethane dispersion comprising at least one isocyanate terminated polyurethane prepolymer prepared by reacting in the presence of at least one pyrrolidone selected from the group consisting of N-n-butylpyrrolidone, N-isobutylpyrrolidone, N-sec-butylpyrrolidone and N-tert-butylpyrrolidone, a mixture (M) which comprises: at least one polyisocyanate compound (a), at least one polyol compound (b), having a molecular weight Mw of 200 to 8000 and a hydroxyl functionality of 1.5 to 6, and at least one water dispersible enhancing component having at least one hydrophilic group or potentially hydrophilic group in water.